EHA 2021: Journaal AML

Prof. dr. Gerwin Huls is vanuit Groningen te gast om samen met Inge Diepman het belangrijkste EHA-nieuws op het gebied van AML door te nemen. Aansluitend geeft prof. dr. Arjan van de Loosdrecht een samenvatting van het congresnieuws over MDS.

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

AML

1. MEASURABLE RESIDUAL DISEASE RESPONSE IN ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE
2. EFFICACY AND SAFETY OF VENETOCLAX IN COMBINATION WITH GILTERITINIB FOR RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: UPDATED ANALYSES OF A PHASE 1B STUDY
3. A PHASE IB/II STUDY OF IVOSIDENIB WITH VENETOCLAX +/- AZACITIDINE IN IDH1-MUTATED MYELOID MALIGNANCIES
4. FLAVIDA CHEMOTHERAPY INDUCES MRD-NEGATIVE REMISSION IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
5. SEQUENTIAL NCRI AML TRIALS SHOW CONSISTENT BENEFIT FOR RIC TRANSPLANT IN CR1 FOR OLDER PATIENTS >60YEARS THAT IS INDEPENDENT OF MRD STATUS AFTER FIRST INDUCTION
6. A UNIFIED CLASSIFICATION AND RISK STRATIFICATION ALGORITHM TO SUPPORT CLINICAL DECISIONS IN ACUTE MYELOID LEUKEMIA

MDS

1. ACTIVATION OF DISTINCT INFLAMMATORY PATHWAYS IS DRIVEN BY GENETICS IN MDS
2. Educational session: Diagnosis in hematological diseases: Morphology and flow cytometry (registratie nodig)
3. E-CADHERIN CONTROLS ERYTHROPOIESIS: A NOVEL AVENUE TO ANEMIA TREATMENT
4. BENEFIT OF CONTINUING LUSPATERCEPT THERAPY IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO DID NOT ACHIEVE RED BLOOD CELL TRANSFUSION INDEPENDENCE BY WEEK 25 IN THE MEDALIST STUDY
5. LUSPATERCEPT REDUCES RED BLOOD CELL TRANSFUSIONS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES REGARDLESS OF BASELINE TRANSFUSION BURDEN IN THE MEDALIST STUDY
6. SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY
7. PHASE II STUDY OF THE IDH2-INHIBITOR ENASIDENIB IN PATIENTS WITH HIGH-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROMES (MDS)
8. A PHASE 1, DOSE ESCALATION TRIAL WITH NOVEL ORAL IRAK4 INHIBITOR CA-4948 IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME – INTERIM REPORT

Bekijk hier het volledige overzicht van onze EHA 2021 coverage.